Novartis Starts 'Strategic Review' Of India Listed Business Amid Reports Of Sale Talks
Media reports suggest that drugmaker Dr. Reddy's Laboratories Ltd. is in the race to acquire the Novartis AG's stake in Novartis India.17-02-2024
17-02-2024
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201517-02-2024
NOVARTIS INDIA LTD. - 500672 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Ms. Gira Sardesai (DIN: 02610502) as an Additional Director (Designated as Non-Executive and Independent Director)17-02-2024
NOVARTIS INDIA LTD. - 500672 - Announcement under Regulation 30 (LODR)-Cessation
Cessation by virtue of completion of tenure of Mr. Jai Hiremath (DIN: 00062203) as an Independent Director17-02-2024
NOVARTIS INDIA LTD. - 500672 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Novartis India Limited Held Today I.E. Saturday, February 17, 2024
Outcome of the meeting of the Board of Directors of Novartis India Limited held today i.e. Saturday, February 17, 202417-02-2024
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201509-02-2024
NOVARTIS INDIA LTD. - 500672 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201506-02-2024
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201530-01-2024
NOVARTIS INDIA LTD. - 500672 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication regarding Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 202327-01-2024